$5.00
Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Relmada Therapeutics Joins Russell 2000, Russell 3000 Indexes
Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
Overview
52-week range
$0.52
$8.00
60% of range
Avg surprise (last 2)
-21.1%
Avg reaction (last 2)
-2.0%
50% positive
Latest IV / EM
79%
EM ±18.0% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.22 | $-0.18 | -22.2% | +62.1% | +1.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.30 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.30 | $-0.25 | -20.0% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.58 | — | — | — | -5.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.72 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.59 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.72 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.73 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.84 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | AMC | -$0.21 | -$0.30 | +30.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-19M | — | $-10M | $-10M | $-18M | — | $-23M | $-19M |
| Net income | $-19M | — | $-10M | $-10M | $-18M | — | $-22M | $-18M |
| EPS (diluted) | $-0.22 | — | $-0.30 | $-0.30 | $-0.58 | — | $-0.72 | $-0.59 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $10M | $3M | $1M | $1M | $1M | $4M | $1M | $2M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $235M | $94M | $15M | $21M | $28M | $46M | $56M | $71M |
| Total assets | $235M | $94M | $15M | $21M | $28M | $46M | $56M | $71M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $17M | $7M | $5M | $5M | $5M | $10M | $8M | — |
| Total equity | $219M | $87M | $9M | $16M | $22M | $36M | $48M | $61M |